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Abstract 
Background: The Plasmodium falciparum multidrug resistance 1 (PfMDR1), P. falciparum  Ca2+-ATPase (PfATP6) and 
Kelch-13 propeller domain (PfK13) loci are molecular markers of parasite susceptibility to anti-malarial drugs. Their 
frequency distributions were determined in the isolates collected from children with severe malaria originating from 
three African countries.
Methods: Samples from 287 children with severe malaria [(Gabon: n = 114); (Ghana: n = 89); (Kenya: n = 84)] were 
genotyped for pfmdr1, pfatp6 and pfk13 loci by DNA sequencing and assessing pfmdr1 copy number variation (CNV) 
by real-time PCR.
Results: Pfmdr1-N86Y mutation was detected in 48, 10 and 10% in Lambaréné, Kumasi and Kisumu, respectively. 
At codon 184, the prevalence of the mutation was 73% in Lambaréné, 63% in Kumasi and 49% Kisumu. The S1034C 
and N1042D variants were absent at all three sites, while the frequency of the D1246Y mutation was 1, 3 and 13% in 
Lambaréné, Kumasi and Kisumu, respectively. Isolates with two pfmdr1 gene copy number predominantly harboured 
the N86Y wild-type allele and were mostly found in Kumasi (10%) (P < 0.0001). Among the main pfmdr1 haplotypes 
(NFD, NYD and YFD), NYD was associated with highest parasitaemia (P = 0.04). At the pfatp6 locus, H243Y and A623E 
mutations were observed at very low frequency at all three sites. The prevalence of the pfatp6 E431K variant was 6, 18 
and 17% in Lambaréné, Kumasi and Kisumu, respectively. The L263E and S769N mutations were absent in all isolates. 
The pfk13 variants associated with artemisinin resistance in Southeast Asia were not observed. Eleven novel substitu-
tions in the pfk13 locus occurring at low frequency were observed.
Conclusions: Artemisinins are still highly efficacious in large malaria-endemic regions though declining efficacy 
has occurred in Southeast Asia. The return of chloroquine-sensitive strains following the removal of drug pressure 
is observed. However, selection of wild-type alleles in the multidrug-resistance gene and the increased gene copy 
number is associated with reduced lumefantrine sensitivity. This study indicates a need to constantly monitor drug 
resistance to artemisinin in field isolates from malaria-endemic countries.
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Background
Malaria still claims hundreds of thousand deaths in sub-
Saharan Africa, mostly children under the age of five and 
pregnant women. The spread of artemisinin-resistant 
Plasmodium falciparum parasites from Southeast Asia 
to Africa is foreseen. Following the current World Health 
Organization (WHO) recommendation, artemisinin-
based combination therapy (ACT) is the first-line 
treatment of severe malaria [1]. Failure of ACT is well 
documented in Western Cambodia and the Thai-Myan-
mar border [2–4]. As a result, the WHO has developed 
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strategies to contain the spread of resistant parasites to 
other countries [5].
It is clearly important to identify resistant phenotypes 
and constantly monitor for artemisinin resistance. Defi-
nitions of artemisinin resistance range from persistence 
of parasites on the third day after drug administra-
tion [6], an increased parasite clearance half-life [7, 8], 
a reduced parasite clearance rate [3, 9, 10] and, finally, a 
treatment failure of ACT [11], although these are debated 
[11–14] and ACT failures also arise because of failure of 
partner drugs of artemisinins. The P. falciparum multid-
rug resistance 1 (PfMDR1) locus on chromosome 5 and 
the P. falciparum  Ca2+-ATPase (PfATP6) locus on chro-
mosome 1 genes may also modulate susceptibility of the 
parasites to artemisinins [15–18]. PfATP6, a candidate 
marker for artemisinin susceptibility [16, 19], is a sarco-
endoplasmic reticulum calcium-ATPase (serca)-type 
calcium pump of the parasite suggested to be the target 
for artemisinins [15]. Increase in the gene copy number 
(copy number variation, CNV) of pfmdr1 [20–22], which 
encodes an ATP-binding cassette transporter homologue 
of the P-glycoprotein 1 [23] is also involved in multid-
rug resistance, including to artemisinins [24]. Recently, 
a new locus was identified, the kelch protein located on 
chromosome 13 (PfK13 propeller); pfk13 mutations asso-
ciated with clinical artemisinin resistance in Cambo-
dia [25], and in vitro ring-stage survival rates [26], have 
now spread across Southeast Asia and South China [27, 
28] and have shown to also arise independently [29]. For 
these reasons, mutations in the pfatp6, pfmdr1 and pfk13 
genes may be useful molecular markers of artemisinin 
resistance [25, 30–32].
This is a sub-study conducted by the “Severe Malaria in 
African Children” (SMAC) consortium [33]. The goal of 
this study was to describe parasite polymorphisms at the 
pfmdr1, pfatp6 and pfk13 loci, including the pfmdr1 copy 
number in West, Central and East African children with 
severe malaria.
Methods
Study design and sample collection
Two hundred and ninety-six children aged 0.5–10 years 
(120 in Lambaréné, Gabon, 90 in Kumasi, Ghana, 86 in 
Kisumu, Kenya) were randomly selected from the SMAC 
study [33]. Blood samples from all patients were collected 
in heparinized tubes. Storage and transport of specimens 
were done using a cold chain transport tool for subse-
quent molecular analyses.
PfMDR1, PfATP6 and PfK13 genotyping
Genomic DNA was isolated using the QIAamp DNA 
mini blood kit (Qiagen, Hilden, Germany). The pfmdr1 
mutations N86Y, Y184F, S1034C, N1042D and D1246Y 
were screened by nested PCR using primer pairs 
described elsewhere [34]. The pfatp6 mutations H243Y, 
L263E, E431K, A623E and S769N were screened by PCR 
using the primer pairs designed by Zakeri et  al. [35]. 
Mutations M476I, Y493H, R539T, I543T and C580Y 
in the pfk13 gene were screened using the primer pairs 
indicated by Ariey et  al. [25]. In brief, 10 ng of parasite 
genomic DNA were added to a 20  µL reaction mixture 
containing 1× PCR buffer (20  mM Tris–HCl pH 8.4, 
50  mM KCl, 2.5  mM of  MgCl2), 0.125  mM of dNTPs, 
0.25  mM of each primer and 1U Taq DNA polymerase 
(Qiagen, Hilden, Germany). The PCR reaction was run 
on a PTC-200 Thermal cycler (MJ Research, Waltham, 
USA). PCR products were visualized through electro-
phoresis on a 1.2% agarose gel stained with SYBR green 
I in 1× Tris-electrophoresis buffer (90 mM Tris–acetate, 
pH 8.0, 90 mM boric acid, 2.5 mM EDTA). Subsequently, 
PCR products were purified (Exo-SAP-IT, USB, Affym-
etrix, Santa Clara, CA, USA) and directly used as tem-
plates for DNA sequencing using the BigDye terminator 
v. 1.1 cycle sequencing kit (Applied Biosystems, Foster 
City, USA) on an ABI 3130XL DNA sequencer. Polymor-
phisms were identified by assembling the sequences with 
the reference sequence of the pfmdr1 (NC_004326.1), 
pfatp6 (NC_004325.1) and pfk13 (NC_004331.2) genes 
using the Codoncode Aligner 4.0 software and visually 
reconfirmed from their electropherograms.
PfMDR1 copy number
The pfmdr1 gene copy number was estimated by TaqMan 
real-time PCR using the hydrolysis probes as previ-
ously described [36]. In brief, 10  ng of genomic DNA 
were added to a 25  µL reaction mixture containing 1× 
TaqMan buffer [8% glycerol, 0.625U DNA polymerase, 
5.5  mmol/L  MgCl2, 300  µmol/L dNTPs, 600  nmol/L 
passive reference dye ROX (5-carboxy-X-rhodamine), 
pH 8.3], 300 nmol/L of each primer, 100 nmol/L of each 
probe, and 5 µL of the template DNA. The real-time PCR 
reaction was run on a Corbett device (Research RG-3000, 
Qiagen, Hilden, Germany). The thermal conditions after 
a pre-incubation step (95  °C, 5  min) were 50 cycles of 
95  °C for 15 s and 58  °C for 1 min. Genomic DNA from 
P. falciparum reference strain 3D7 was used as calibrator 
and P. falciparum ß-tubulin, a house-keeping gene, was 
used as reference gene. For multiple pfmdr1 gene copy 
numbers, DNA from the Dd2 clone was used as control. 
The  2−ΔΔCt method of relative quantification was used to 
estimate the gene copy number [37]. Each sample was 
run in triplicate along with the reference DNA samples 
from clones 3D7 and Dd2, which are known to have 
a pfmdr1 gene copy number of 1 and 2–4, respectively. 
The mean and standard deviation of the three threshold 
cycle (Ct) values were calculated for each sample. The 
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experiment was repeated if one of the following results 
was obtained: ΔΔCt spread >1.5; Ct values >35; or copy 
number value  =  1.3–1.6 [36]. Copy number estimates 
were rounded to the nearest integer and parasites with 
more than 1.5 copies were considered multiple copies 
[36]. A sample was considered to carry one copy of the 
gene if the N-fold copy number was between 0.5 and 1.5 
(0.5 < N-fold < 1.5).
Statistical analysis
Data were analysed using GraphPad Prism (Graph-
Pad software Inc, La Jolla, CA). Mann–Whitney U and 
Kruskal–Wallis H One-way ANOVA tests were executed 
to determine possible associations of parasitaemia with 
the increased gene copy number and with the haplotypes 
of the genes investigated. Dunn’s multiple comparison 
test was used to test for differences among study sites. 
The level of significance was set to a P value of <0.05.
Results
In total, 296 children with severe malaria were enrolled 
in this study. Available for genetic analyses were 287 
patients.
PfMDR1 polymorphisms
All 287 samples were successfully genotyped for pfmdr1 
mutations. The frequency distribution of genetic variants 
identified is given in Table  1. The S1034C and N1042D 
mutations were absent at all three sites, while the fre-
quency of the D1246Y mutation was 1, 3 and 13% in 
Lambaréné, Kumasi and Kisumu, respectively.
In Lambaréné, the prevalence of the wild-type N86Y 
allele was 40%. The frequency of mixed genotypes was 
12%. At codon 184, the frequency of the wild-type and 
mutant Y184F alleles was 25 and 73%, respectively, 
whereas the prevalence of mixed genotypes was 2%. The 
double mutations N86Y/Y184F, and N86Y/D1246Y were 
observed in 51 (45%) and 1 (1%) samples, respectively.
In Kumasi, the majority of samples (73%) carried the 
wild-type N86Y allele. The prevalence of mixed geno-
types was 17%. The prevalence of the wild-type Y184F 
allele was 30, and 7% for the mixed genotypes. The prev-
alence of double mutations N86Y/Y184F, and N86Y/
D1246Y was 9 and 1%, respectively. There was only one 
sample with the triple mutant N86Y-Y184F-D1246Y 
allele.
In Kisumu, 82% of samples carried the wild-type allele 
N86Y, and 8% had mixed genotypes. The frequency of 
samples carrying the wild-type Y184F allele 44%. The 
samples with mixed genotypes were 7%. Two samples 
(2%) had the double mutant N86Y/Y184F, and 4 (5%) had 
the double mutant N86Y/D1246Y. One sample carried 
the triple mutant N86Y-Y184F-D1246Y allele.
PfMDR1 copy number
The copy number of the pfmdr1 was successfully deter-
mined and results were available for 285 isolates. Two 
isolates, one each in Lambaréné and Kisumu, were 
removed from the analysis because of inconsistent 
results. The overall pfmdr1 copy number mean was 0.89 
(range 0.5–1.9), 1.2 (range 0.5–1.9) and 0.95 (range 0.5–
1.7) in Lambaréné, Kumasi and Kisumu, respectively. 
With the control DNA, the results were reproducible 
with a mean copy number of 1.1 and a standard devia-
tion of 0.18 for the 3D7 strain. The Dd2 control gave a 
mean copy number of 3.98 with a standard deviation of 
0.38. When rounded to an integer, three, nine and one 
isolates with two gene copy numbers were observed in 
Lambaréné, Kumasi and Kisumu, respectively. The val-
ues of the pfmdr1 copy number from the three study 
sites are depicted in Fig. 1. When rounded to the nearest 
integer, 1 gene copy number was found in 97, 90 and 99% 
isolates from Lambaréné, Kumasi and Kisumu, respec-
tively. There was a significant difference of the pfmdr1 
copy number among the parasites from the three study 
sites (P  <  0.0001). Dunn’s multiple comparison showed 
that parasites retrieved in samples from Kumasi had 
more copy numbers than identified in those from Lam-
baréné and Kisumu. In this study, the pfmdr1 copy num-
ber was not related to the baseline parasitaemia [Mean 
parasitaemia, Kisumu = 183,233 (range 7452–1,677,780), 
Kumasi  =  171,835 (range 6240–1,209,000) and 
Table 1 Frequency distribution of mutant pfmdr1 and pfatp6 alleles in isolates from Lambaréné, Kumasi and Kisumu
There were no mutant alleles at the following codons: pfmdr1 S1034C, N1042D and pfatp6 L263E, S769N
Site (N) Number (%) of samples with allelic change at these codons
Pfmdr1 Pfatp6
86Y 184F 1246Y 243Y 431K 623E
Lambaréné (114) 55 (48) 83 (73) 1 (1) 1 (1) 6 (6) 1 (1)
Kumasi (89) 9 (10) 56 (63) 3 (3) 1 (1) 13 (18) 1 (1)
Kisumu (84) 8 (10) 41 (49) 11 (13) 2 (3) 13 (17) 1 (1)
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Lambaréné = 80,986 (range 5376–745,100)]. The isolates 
with an increased copy number were found to harbour 
predominantly the N86Y wild-type allele alone (9/13) or 
combined with the mutant allele (11/13) compared to the 
mutant allele N86Y alone (2/13).
PfMDR1 haplotypes
The pfmdr1 haplotypes were reconstructed including the 
mutations N86Y, Y184F and D1246Y. The isolates with a 
mixture of two haplotypes were each counted as carrying 
both. In total, eight different haplotypes were observed. 
In Lambaréné, the haplotype YFD was the most prevalent 
one, occurring at a frequency of 57%, followed by NFD 
(30%), NYD (24%), YYD (5%) and YYY (1%). In Kumasi, 
the most prevalent haplotype was NFD (60%) followed 
by NYD (34%), YFD (23%), YYY (3%) and NYY (2%). 
The other haplotypes NFY, YYD and YFY all occurred 
at a frequency of 1%. In Kisumu, the haplotype NFD was 
the most prevalent, occurring at a frequency of 51%, fol-
lowed by NYD (37%), NYY and YFD both occurring at 
a frequency of 7%, YYD and YYY each at 6%, NFY (2%) 
and YFY (1%). The most prevalent haplotypes associated 
with increased pfmdr1 copy number were NFD, NYD 
and YFD occurring six, five and four times, respectively. 
For these main haplotypes (NFD, NYD and YFD), the 
mean parasitaemia was significantly different (P = 0.04) 
and this difference was observed between the haplotypes 
NYD and YFD (P = 0.012).
PfATP6 polymorphisms
Of the 287 collected samples, only 250 samples 
(99/114, 74/89 and 77/84 in Lambaréné, Kumasi and 
Kisumu, respectively) were successfully genotyped for 
pfatp6 mutations (Table  1). In the samples collected in 
Lambaréné, the prevalence of the pfatp6 H243Y, E431K 
and A623E mutant alleles was 1, 6 and 1%, respectively. 
The frequency of the mixed genotypes at codon 243 was 
1%. In Kumasi, two isolates harboured the mixed geno-
types at codons 243 and 623 at a frequency of 1% each, 
respectively. Thirteen (18%) samples carried the mutant 
allele E431K while two samples (1%), one each car-
ried the mutant H243Y and A623E alleles, respectively. 
In Kisumu, the frequency of the mutant alleles E431K, 
H243Y and A623E was 17, 3 and 1%, respectively. The 
prevalence of the mixed genotypes only found at codon 
A623E was 3%.
PfATP6 haplotypes
The pfatp6 haplotypes were reconstructed using the 
mutations H243Y, E431K and A623E. Isolates with a mix-
ture of two haplotypes were counted as carrying both. 
Five haplotypes were investigated. The HEA haplotype 
was the most prevalent one, occurring at a frequency 
of 92, 80, and 81% in Lambaréné, Kumasi and Kisumu, 
respectively. In Lambaréné, the other haplotypes were 
HKA, HEE and YEA occurring at frequencies of 6, 1 
and 2%, respectively. In Kumasi, the haplotypes HKA, 
HEE, YEA and YKA were found at frequencies of 18, 3, 
1 and 1%, respectively. In Kisumu, the haplotypes HKA, 
HEE and YEA were found at frequencies of 17, 4 and 3%, 
respectively. There was no association of the mean para-
sitaemia with any of the haplotypes.
PfK13 polymorphisms
The nonsynonymous mutations M476I, Y493H, R539T, 
I543T and C580Y, which were previously shown to be 
associated with an increased parasite clearance half-life 
time in Cambodia were absent in these samples. How-
ever, several yet unrecognized variants were identified 
individually in eleven parasites (three, two and six in 
Lambaréné, Kumasi and Kisumu, respectively), albeit at 
very low frequencies (Table 2).
Discussion
In the absence of an effective malaria vaccine, treat-
ment failures associated with ACT (TFACT) will hamper 
global efforts in reducing malaria mortality and morbid-
ity. Besides studies on Africans, one of the most affected 
populations, highlighted the significant contribution of 
host genetics towards the stabilisation of these two indi-
cators of health status [38–41]. A previous study has 
shown for the first time that the pfmdr1 N86Y polymor-
phism is associated with delayed parasite clearance when 
artesunate was used in monotherapy [33]. This finding 
may be of importance, as it demonstrates in  vivo mod-
ulation of the efficacy of artesunate, the drug of choice 
against severe malaria. However, there is an important 
Fig. 1 Distribution of pfmdr1 gene copy number in isolates from 
Lambaréné, Kumasi and Kisumu
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need to clearly define artemisinin resistance owing to 
the large number of definitions found in the literature. 
Besides inclusive debates are rather welcome if the goal 
is to tackle the problem of multidrug-resistant parasites 
[12]. In the meantime, continuous monitoring of the 
molecular markers of anti-malarial drug resistance will 
help to prevent the spread of resistant strains and serve 
as basis for future update of the treatment policy.
Concerning the frequency distribution of the pfmdr1 
mutations, when comparing with previous studies [42], 
an increased prevalence of the wild-type allele N86Y 
was observed in Gabon. This allele is reported to be 
associated with exposure to the anti-malarial drug com-
bination artemether–lumefantrine (AL) [43, 44]. The 
mutation N86Y has previously been associated with 
a lower 50% inhibitory concentration (IC50) for arte-
misinin and dihydroartemisinin, as compared with the 
wild-type allele [18]. However, a recent study showed 
that the pfmdr1 N86Y variant was associated with 
prolonged parasite clearance in  vivo [33]. Its high fre-
quency in Lambaréné might be alarming but parasites 
in that region are still sensitive to artemisinins. Further 
studies assessing the sensitivity of these parasites over 
time are needed. In Kumasi, the findings reported here 
were consistent with the study published by Kwansa-
Bentum et  al. [45]. In Kisumu, the prevalence of the 
pfmdr1 wild-type allele N86Y was higher compared to 
a previous study [46]. This allele has been associated 
in  vitro with a three to fourfold increase of the lume-
fantrine IC50 values, as compared to the mutant N86Y 
allele [47], and suggested together with other pfmdr1 
polymorphisms to be important determinants of para-
site sensitivity to anti-malarials [48]. In addition, the 
pfmdr1 wild-type allele N86Y is reported to be predom-
inant in recurrent infections [49] and to increase in a 
fivefold degree the risk of recrudescence in individuals 
treated with AL [50]. These findings support the need 
of a constant monitoring of the parasite susceptibility to 
AL in Kumasi and Kisumu.
The mutations S1034C and N1042C, which have been 
reported to reduce parasite resistance to mefloquine [51] 
were not observed at all in this study. Regarding the vari-
ant D1246Y, a threefold increased prevalence from 4% 
[46] to 13% in Kisumu, compared to the lower preva-
lence of D1246Y of 9% [42] to 1% in Lambaréné, and of 
14% [52] to 3% in Kumasi was noted. Sidhu et  al. [53] 
have reported that the combination of the mutant alleles 
S1034C-N1042D-D1246Y, which occurs frequently in 
South America, was associated with increased para-
site susceptibility to artemisinin. However, in this study, 
S1034C and N1042C were absent, except D1246Y. This 
finding suggests that there is some selective pressure 
exerted by the parasite on the drug transporter pfmdr1 
gene at codons 1034 and 1042. The selection of the wild-
type alleles following ACT use is worrying as a higher 
virulence of these wild-type genotypes has been linked to 
febrile illness [54].
PfMDR1 gene amplification has been reported to be 
selected by the use of mefloquine, artesunate, lumefan-
trine and quinine [36, 52, 55–57]. Uhlemann et  al. [56] 
found 5% of P. falciparum isolates in Lambaréné carry-
ing two copies of the pfmdr1 gene, while 7 years later the 
same authors did not identify any isolates with multi-
copies. In the present study, 3% of the isolates were found 
carrying two copies. This indicates a possible circulation 
of parasites carrying several copies of the pfmdr1 gene 
in Lambaréné at a low prevalence. The low frequency of 
isolates with pfmdr1 multicopies observed in Kisumu is 
consistent with previous studies [58, 59]; and in Ghana, 
these findings are in agreement with previous work [52, 
60]. The pfmdr1 gene amplification is one of the best 
indicators for monitoring parasite resistance to treatment 
with artesunate mefloquine combination, and some but 
not all parasites with increased pfmdr1 gene copies had 
a reduced sensitivity to artesunate in the Thai-Myanmar 
border region [61]. Thus, the determination of pfmdr1 
gene amplification might become an appropriate tool for 
the assessment of parasite susceptibility in Ghana [52]. 
Table 2 Mutations in the Kelch-13 propeller domain (pfk13) of isolates from Lambaréné, Kumasi and Kisumu
Codon position Amino acid reference Nucleotide reference Amino acid mutation Nucleotide mutation Site
549 S tct S tcC Kumasi
553 P ccg P ccA Kisumu
578 A gct S Tct Kisumu
589 V gtc I Atc Lambaréné
589 V gtc V gtT Lambaréné
639 G ggt G ggC Kumasi
645 N aac N aaT Lambaréné
666 V gta V gtG Kisumu
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The majority of isolates with two copies of the pfmdr1 
gene also carried the wild-type N86Y allele compared 
to a few only harbouring the mutant allele. This suggests 
that the wild-type allele has a selective advantage to be 
amplified, although the mutant allele can also have its 
gene amplified [58].
The PfMDR1 haplotype YFD has been reported to be 
associated with increased parasite susceptibility to arte-
misinin derivatives, mefloquine, halofantrine and lume-
fantrine [22, 62, 63]. The high frequency of this haplotype 
in Lambaréné suggests that it contributes to maintain 
parasite susceptibility to artemisinin derivatives, com-
pared to Kumasi and Kisumu where the haplotype was 
found at low frequencies. The pfmdr1 NFD haplotype 
identified at higher prevalences in Kumasi and Kisumu 
than in Lambaréné might decrease parasite susceptibil-
ity to AL as it appears to be selected by AL [43, 64, 65]. 
Therefore, it must be well monitored in countries using 
AL [52], as the wild-type allele N86Y and potentially its 
duplication are associated with decreased parasite sus-
ceptibility to AL [36, 44]. Moreover, Malmberg et al. [49] 
showed that NFD followed by the other NYD, YYY and 
YYD haplotypes was significantly linked with resistance 
to higher lumefantrine concentration in vivo in Tanzania.
The pfatp6 L263E and S769N mutations have been 
shown to reduce by allelic exchange parasite susceptibil-
ity to some artemisinins [16, 66] and to increase the IC50 
of artemether [19]. These variants were not observed in 
these samples. L263E was not present in these isolates 
compared to the Greater Mekong subregion [67] though 
identified in field isolates from Tanzania after ACT were 
introduced [68]. Described as a potential molecular 
marker for artemisinin resistance [19], the S769N muta-
tion was not present in this study population. Numerous 
studies have reported this mutation to be rare or absent 
[67, 69–75]. However, when assessed in African isolates, 
this mutation did not correlate with an increased IC50 to 
dihydroartemisinin, the main active compound of arte-
misinin derivatives [76] as investigated with the increased 
IC50 of artemether in isolates from French Guiana [19, 
69, 77]. An explanation could be that either the func-
tionality of this mutation is only linked to artemether, 
or that the distinct genetic makeup of the isolate plays a 
role [76], or that the frequency is still too low to allow for 
reliable conclusions. H243Y was found with low frequen-
cies in the present study. However, its role in modulat-
ing artemisinin resistance is not well characterized [76]. 
The polymorphism E431K, reported by Jambou et al. to 
be linked with an increased artemether IC50 [19], was 
the most prevalent in this study. A previous study has 
reported an increased frequency of the A623E mutation 
after the implementation of ACT in Niger [75], while its 
prevalence in this study was low.
The pfk13 is a polymorphic gene located 5.9  kb 
upstream of the 35  kb region. It is linked with delayed 
parasite clearance [78] and within the region of top-
ranked signatures of selection on chromosome 13 [79]. 
Therefore, it has been proposed to be a reliable marker 
for artemisinin resistance [25]. Among the polymor-
phisms investigated by Ariey et al. [25] the M476I variant 
was acquired in vitro in the F32-ART5 P. falciparum lin-
eage following increased concentrations of artemisinin. 
This polymorphism was absent in these isolates, suggest-
ing that the development of artemisinin resistance in the 
field might differ in vivo and in vitro. The polymorphisms 
Y493H, R539T and C580Y, associated with a significant 
slow-clearing of parasites were also absent in this study. 
Even E612D found in Gambia [80] was absent in these 
isolates, again indicating the enormous heterogeneity of 
malaria parasites in Africa. The absence of these pfk13 
mutations in African isolates highlights two facts: (1) the 
mechanisms of artemisinin resistance in Africa are not 
identical with those observed in Southeast Asia and (2) 
artemisinin resistance occurring in Cambodia and Thai-
land has not spread to Africa yet.
Artemisinin and its derivatives remain highly effica-
cious in the treatment of malaria, including in Africa. The 
declining efficacy of ACT (TFACT) reported in South-
east Asia threatens the global efforts towards the elimi-
nation and eradication of the disease. Selective pressure 
on the multidrug-resistance gene favoured the return of 
chloroquine-sensitive (wild-type pfmdr1 N86Y allele) 
strains as observed in this study and supported by accu-
mulated evidences from previous studies [81, 82]. How-
ever, these alleles have been associated with decreased 
lumefantrine sensitivity. Furthermore, a re-emergence 
and persistence of P. falciparum isolates with multicopies 
of the pfmdr1 gene in some parts of Africa were noted. 
This study indicates the need to continuously monitor 
parasite susceptibility to artemisinin and its derivatives in 
field isolates from malaria-endemic countries.
Abbreviations
PfMDR1: Plasmodium falciparum multidrug resistance 1; PfATP6: Plasmodium 
falciparum  Ca2+-ATPase; PfK13: Plasmodium falciparum Kelch-13 propeller 
domain; CNV: copy number variation; ACT: artemisinin-based combination 
therapy; IC50: half maximum inhibitory concentration; SMAC: Severe Malaria 
in African children; WHO: World Health Organization.
Authors’ contributions
TPV designed the experiments, supervised the experiments, performed 
data analysis and wrote the manuscript. AAA, TA, BRO are involved in patient 
recruitment from respective study sites and are principal investigators for 
SMAC study. PGK and SK contributed to study design and materials. CNN per-
formed the experiments, data analysis and drafted the manuscript. All authors 
read and approved the final manuscript.
Author details
1 Institute of Tropical Medicine, University Tübingen, Wilhelmstrasse 27, 
72074 Tübingen, Germany. 2 Fondation Congolaise pour la Recherche 
Page 7 of 9Nguetse et al. Malar J  (2017) 16:217 
Médicale, Brazzaville, Republic of Congo. 3 Centre de Recherches Médicales 
de Lambaréné, Lambaréné, Gabon. 4 Department of Physiology, University 
of Science and Technology, School of Medical Sciences, Kumasi, Ghana. 
5 Departments of Child Health and Medicine, Komfo Anokye Teaching Hos-
pital, Kumasi, Ghana. 6 Centre for Clinical Research, Kenya Medical Research 
Institute, Kisumu, Kenya. 7 Institute for Infection and Immunity, St George’s 
University of London, London, UK. 8 Vietnamese-German Center for Medical 
Research, Hanoi, Vietnam. 9 Faculty of Medicine, Duy Tan University, Da Nang, 
Vietnam. 
Acknowledgements
We would like to thank the staff and technicians of Lambaréné, Kumasi 
and Kisumu for their assistance in collecting the blood samples and clinical 
data of patients during the study. We express our gratitude to all the study 
participants involved in this study. We also acknowledge Velia Grummes for 
technical help during sequencing procedures. We thank the Severe Malaria in 
African Children (SMAC) consortium.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All relevant data are within the paper.
Consent for publication
All authors read and approved to its final submission.
Ethics approval and consent to participate
Written informed consent was obtained from parents or guardians of all 
participating children. The study was approved by the authorities of each 
study site: the Regional Ethics Committee in Lambaréné (CERIL) for Gabon, 
the Committee on Human Research, Publication and Ethics, Kwame Nkrumah 
University of Science and Technology (KNUST), Kumasi for Ghana, and the 
National Ethics Research Committee, Kenya Medical Research Institute (KEMRI) 
for Kenya.
Funding
This work was funded by a DFG grant (DFG-KU775/17-1) German–African 
cooperation project on infectious diseases. The authors acknowledge the 
support by the Deutsche Forschungsgemeinschaft (DFG) and Open Access 
Publishing Fund of Tübingen University. The work is a part of the SMAC study 
(Trial registry; PACTR201102000277177) funded by European and Developing 
Countries Clinical Trials Partnership (EDCTP; CT.2004.31070.001). The authors 
also acknowledge the support from Central African Network on Tuberculosis, 
and HIV/AIDS (CANTAM).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 2 February 2017   Accepted: 17 May 2017
References
 1. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World 
Health Organization; 2010.
 2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Arte-
misinin resistance in Plasmodium falciparum malaria. N Engl J Med. 
2009;361:455–67.
 3. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, 
et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, 
western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 
2012;12:851–8.
 4. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. 
Emergence of artemisinin-resistant malaria on the western border of 
Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
 5. WHO. Global plan for artemisinin resistance containment (GPARC). 
Geneva: World Health Organization; 2011.
 6. WHO. Global report on antimalarial drug efficacy and drug resistance: 
2000–2010. Geneva: World Health Organization; 2010.
 7. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measure-
ment of parasite clearance in falciparum malaria: the parasite clearance 
estimator. Malar J. 2011;10:339.
 8. White NJ. The parasite clearance curve. Malar J. 2011;10:278.
 9. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced sus-
ceptibility of Plasmodium falciparum to artesunate in southern Myanmar. 
PLoS ONE. 2013;8:e57689.
 10. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Artemisinin 
resistance in Cambodia 1 study C. Evidence of artemisinin-resistant 
malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.
 11. Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resist-
ance: reappraisal as treatment failure with artemisinin combination 
therapy. Trends Parasitol. 2013;29:313–7.
 12. Krishna S, Staines HM, Kremsner PG. Artemisinin resistance and the blame 
game. Clin Infect Dis. 2016;63:1144–5.
 13. Meshnick S. Artemisinin resistance in southeast Asia. Clin Infect Dis. 
2016;63:1527.
 14. Hastings IM, Kay K, Hodel EM. The importance of scientific debate in the 
identification, containment, and control of artemisinin resistance. Clin 
Infect Dis. 2016;63:1527–8.
 15. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura 
M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 
2003;424:957–61.
 16. Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, 
Zuniga FA, et al. A single amino acid residue can determine the sensitivity 
of SERCAs to artemisinins. Nat Struct Mol Biol. 2005;12:628–9.
 17. Cowman AF, Karcz S. Drug resistance and the P-glycoprotein homo-
logues of Plasmodium falciparum. Semin Cell Biol. 1993;4:29–35.
 18. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. 
The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is 
associated with increased sensitivity to the anti-malarials mefloquine and 
artemisinin. Mol Biochem Parasitol. 2000;108:13–23.
 19. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance 
of Plasmodium falciparum field isolates to in vitro artemether and point 
mutations of the SERCA-type PfATPase6. Lancet. 2005;366:1960–3.
 20. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, 
et al. Molecular and pharmacological determinants of the therapeutic 
response to artemether–lumefantrine in multidrug-resistant Plasmodium 
falciparum malaria. Clin Infect Dis. 2006;42:1570–7.
 21. Uhlemann AC, Krishna S. Antimalarial multi-drug resistance in Asia: mech-
anisms and assessment. Curr Top Microbiol Immunol. 2005;295:39–53.
 22. Uhlemann AC, McGready R, Ashley EA, Brockman A, Singhasivanon P, 
Krishna S, et al. Intrahost selection of Plasmodium falciparum pfmdr1 
alleles after antimalarial treatment on the northwestern border of Thai-
land. J Infect Dis. 2007;195:134–41.
 23. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sen-
sitivity and resistance to multiple antimalarials in Plasmodium falciparum. 
Nature. 2000;403:906–9.
 24. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antima-
larial drug-resistance. Acta Trop. 2005;94:181–90.
 25. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, 
et al. A molecular marker of artemisinin-resistant Plasmodium falciparum 
malaria. Nature. 2014;505:50–5.
 26. Amaratunga C, Witkowski B, Khim N, Menard D, Fairhurst RM. Artemisinin 
resistance in Plasmodium falciparum. Lancet Infect Dis. 2014;14:449–50.
 27. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. 
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl 
J Med. 2014;371:411–23.
 28. Huang F, Takala-Harrison S, Jacob CG, Liu H, Sun X, Yang H, et al. A Single 
mutation in K13 predominates in Southern China and is associated with 
delayed clearance of Plasmodium falciparum following artemisinin treat-
ment. J Infect Dis. 2015;212:1629–35.
 29. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, 
et al. Independent emergence of artemisinin resistance mutations among 
Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015;211:670–9.
 30. Greenwood B, Mutabingwa T. Malaria in 2002. Nature. 2002;415:670–2.
Page 8 of 9Nguetse et al. Malar J  (2017) 16:217 
 31. Pulcini S, Staines HM, Pittman JK, Slavic K, Doerig C, Halbert J, et al. 
Expression in yeast links field polymorphisms in PfATP6 to in vitro 
artemisinin resistance and identifies new inhibitor classes. J Infect Dis. 
2013;208:468–78.
 32. Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, 
et al. Drug resistance. K13-propeller mutations confer artemisinin resist-
ance in Plasmodium falciparum clinical isolates. Science. 2015;347:428–31.
 33. Kremsner PG, Adegnika AA, Hounkpatin AB, Zinsou JF, Taylor TE, 
Chimalizeni Y, et al. Intramuscular artesunate for severe malaria in 
African children: a multicenter randomized controlled trial. PLoS Med. 
2016;13:e1001938.
 34. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, 
Sutherland CJ, et al. Amodiaquine and artemether-lumefantrine select 
distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian chil-
dren treated for uncomplicated malaria. Antimicrob Agents Chemother. 
2007;51:991–7.
 35. Zakeri S, Hemati S, Pirahmadi S, Afsharpad M, Raeisi A, Djadid ND. Molec-
ular assessment of atpase6 mutations associated with artemisinin resist-
ance among unexposed and exposed Plasmodium falciparum clinical 
isolates to artemisinin-based combination therapy. Malar J. 2012;11:373.
 36. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun 
L, et al. Mefloquine resistance in Plasmodium falciparum and increased 
pfmdr1 gene copy number. Lancet. 2004;364:438–47.
 37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2−∆∆CT method. Methods. 
2001;25:402–8.
 38. Nguetse CN, Meyer CG, Adegnika AA, Agbenyega T, Ogutu BR, Kremsner 
PG, et al. Glucose-6-phosphate dehydrogenase deficiency and reduced 
haemoglobin levels in African children with severe malaria. Malar J. 
2016;15:346.
 39. Nguetse CN, Kremsner PG, Velavan TP. FOXO3A regulatory polymorphism 
and susceptibility to severe malaria in Gabonese children. Immunogenet-
ics. 2015;67:67–71.
 40. Koukouikila-Koussounda F, Ntoumi F, Ndounga M, Tong HV, Abena AA, 
Velavan TP. Genetic evidence of regulatory gene variants of the STAT6, 
IL10R and FOXP3 locus as a susceptibility factor in uncomplicated malaria 
and parasitaemia in Congolese children. Malar J. 2013;12:9.
 41. Velavan TP, Buyukyazici B, Kremsner PG, Kun JF. Combined promoter hap-
lotypes of the IL10R genes are associated with protection against severe 
malaria in Gabonese children. Immunogenetics. 2012;64:87–95.
 42. Mayengue PI, Kalmbach Y, Issifou S, Kremsner PG, Ntoumi F. No variation 
in the prevalence of point mutations in the Pfcrt and Pfmdr1 genes in 
isolates from Gabonese patients with uncomplicated or severe Plasmo-
dium falciparum malaria. Parasitol Res. 2007;100:487–93.
 43. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, 
et al. Temporal trends of molecular markers associated with artemether-
lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J. 
2013;12:103.
 44. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjork-
man A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N 
coding alleles by artemether–lumefantrine (Coartem). J Infect Dis. 
2005;191:1014–7.
 45. Kwansa-Bentum B, Ayi I, Suzuki T, Otchere J, Kumagai T, Anyan WK, et al. 
Plasmodium falciparum isolates from southern Ghana exhibit polymor-
phisms in the SERCA-type PfATPase6 though sensitive to artesunate 
in vitro. Malar J. 2011;10:187.
 46. Spalding MD, Eyase FL, Akala HM, Bedno SA, Prigge ST, Coldren RL, et al. 
Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid 
emergence of pfdhps resistance mutations at codons 581 and 613 in 
Kisumu, Kenya. Malar J. 2010;9:338.
 47. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnadig N, Uhlemann AC, 
et al. Globally prevalent PfMDR1 mutations modulate Plasmodium 
falciparum susceptibility to artemisinin-based combination therapies. Nat 
Commun. 2016;7:11553.
 48. Duraisingh MT, Roper C, Walliker D, Warhurst DC. Increased sensitivity to 
the antimalarials mefloquine and artemisinin is conferred by muta-
tions in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol. 
2000;36:955–61.
 49. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Bjorkman A, et al. 
Plasmodium falciparum drug resistance phenotype as assessed by patient 
antimalarial drug levels and its association with pfmdr1 polymorphisms. J 
Infect Dis. 2013;207:842–7.
 50. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, 
Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine 
resistance transporter and multidrug resistance 1 genes: parasite risk 
factors that affect treatment outcomes for P. falciparum malaria after 
artemether–lumefantrine and artesunate–amodiaquine. Am J Trop Med 
Hyg. 2014;91:833–43.
 51. Ruetz S, Delling U, Brault M, Schurr E, Gros P. The pfmdr1 gene of Plasmo-
dium falciparum confers cellular resistance to antimalarial drugs in yeast 
cells. Proc Natl Acad Sci USA. 1996;93:9942–7.
 52. Duah NO, Matrevi SA, de Souza DK, Binnah DD, Tamakloe MM, Opoku VS, 
et al. Increased pfmdr1 gene copy number and the decline in pfcrt and 
pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after 
the change of anti-malarial drug treatment policy. Malar J. 2013;12:377.
 53. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to 
quinine resistance and enhance mefloquine and artemisinin sensitivity in 
Plasmodium falciparum. Mol Microbiol. 2005;57:913–26.
 54. Tukwasibwe S, Mugenyi L, Mbogo GW, Nankoberanyi S, Maiteki-Sebuguzi 
C, Joloba ML, et al. Differential prevalence of transporter polymorphisms 
in symptomatic and asymptomatic falciparum malaria infections in 
Uganda. J Infect Dis. 2014;210:154–7.
 55. Ashley EA, White NJ. Artemisinin-based combinations. Curr Opin Infect 
Dis. 2005;18:531–6.
 56. Uhlemann AC, Ramharter M, Lell B, Kremsner PG, Krishna S. Amplification 
of Plasmodium falciparum multidrug resistance gene 1 in isolates from 
Gabon. J Infect Dis. 2005;192:1830–5.
 57. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, 
Fidock DA. Decreasing pfmdr1 copy number in Plasmodium falciparum 
malaria heightens susceptibility to mefloquine, lumefantrine, halofan-
trine, quinine, and artemisinin. J Infect Dis. 2006;194:528–35.
 58. Holmgren G, Bjorkman A, Gil JP. Amodiaquine resistance is not related 
to rare findings of pfmdr1 gene amplifications in Kenya. Trop Med Int 
Health. 2006;11:1808–12.
 59. Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, et al. The 
role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, meflo-
quine and lumefantrine susceptibility in western-Kenya P. falciparum 
samples during 2008-2011. PLoS ONE. 2013;8:e64299.
 60. Witkowski B, Nicolau ML, Soh PN, Iriart X, Menard S, Alvarez M, 
et al. Plasmodium falciparum isolates with increased pfmdr1 copy 
number circulate in West Africa. Antimicrob Agents Chemother. 
2010;54:3049–51.
 61. Na-Bangchang K, Muhamad P, Ruaengweerayut R, Chaijaroenkul W, 
Karbwang J. Identification of resistance of Plasmodium falciparum to 
artesunate-mefloquine combination in an area along the Thai-Myanmar 
border: integration of clinico-parasitological response, systemic drug 
exposure, and in vitro parasite sensitivity. Malar J. 2013;12:263.
 62. Nawaz F, Nsobya SL, Kiggundu M, Joloba M, Rosenthal PJ. Selection of 
parasites with diminished drug susceptibility by amodiaquine-containing 
antimalarial regimens in Uganda. J Infect Dis. 2009;200:1650–7.
 63. Wurtz N, Fall B, Pascual A, Diawara S, Sow K, Baret E, et al. Prevalence of 
molecular markers of Plasmodium falciparum drug resistance in Dakar, 
Senegal. Malar J. 2012;11:197.
 64. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, 
Theander TG, et al. Prevalence of single nucleotide polymorphisms in the 
Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe 
District in Tanzania before and after introduction of artemisinin-based 
combination therapy. Am J Trop Med Hyg. 2011;85:979–83.
 65. Thomsen TT, Madsen LB, Hansson HH, Tomas EV, Charlwood D, Bygbjerg 
IC, et al. Rapid selection of Plasmodium falciparum chloroquine resistance 
transporter gene and multidrug resistance gene-1 haplotypes associated 
with past chloroquine and present artemether–lumefantrine use in Inham-
bane District, southern Mozambique. Am J Trop Med Hyg. 2013;88:536–41.
 66. Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S. 
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) 
L263E mutation in artemisinin action and resistance. Antimicrob Agents 
Chemother. 2010;54:3842–52.
 67. Miao M, Wang Z, Yang Z, Yuan L, Parker DM, Putaporntip C, et al. Genetic 
diversity and lack of artemisinin selection signature on the Plasmo-
dium falciparum ATP6 in the Greater Mekong Subregion. PLoS ONE. 
2013;8:e59192.
Page 9 of 9Nguetse et al. Malar J  (2017) 16:217 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 68. Chilongola J, Ndaro A, Tarimo H, Shedrack T, Barthazary S, Kaaya R, et al. 
Occurrence of pfatpase6 single nucleotide polymorphisms associated 
with artemisinin resistance among field isolates of Plasmodium falcipa-
rum in north-eastern Tanzania. Malar Res Treat. 2015;2015:279028.
 69. Jambou R, Martinelli A, Pinto J, Gribaldo S, Legrand E, Niang M, et al. 
Geographic structuring of the Plasmodium falciparum sarco(endo)
plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversity. PLoS ONE. 
2010;5:e9424.
 70. Tanabe K, Zakeri S, Palacpac NM, Afsharpad M, Randrianarivelojosia M, 
Kaneko A, et al. Spontaneous mutations in the Plasmodium falciparum 
sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase (PfATP6) gene 
among geographically widespread parasite populations unexposed to 
artemisinin-based combination therapies. Antimicrob Agents Chem-
other. 2011;55:94–100.
 71. Tahar R, Ringwald P, Basco LK. Molecular epidemiology of malaria in Cam-
eroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates 
of Plasmodium falciparum and sequence analysis of the P. falciparum 
ATPase 6 gene. Am J Trop Med Hyg. 2009;81:13–8.
 72. Zhang G, Guan Y, Zheng B, Wu S, Tang L. No PfATPase6 S769N mutation 
found in Plasmodium falciparum isolates from China. Malar J. 2008;7:122.
 73. Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, do Rosario V, Cravo 
P. Malaria parasites can develop stable resistance to artemisinin but lack 
mutations in candidate genes atp6 (encoding the sarcoplasmic and 
endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob 
Agents Chemother. 2006;50:480–9.
 74. Mugittu K, Genton B, Mshinda H, Beck HP. Molecular monitoring of 
Plasmodium falciparum resistance to artemisinin in Tanzania. Malar J. 
2006;5:126.
 75. Ibrahim ML, Khim N, Adam HH, Ariey F, Duchemin JB. Polymorphism 
of PfATPase in Niger: detection of three new point mutations. Malar J. 
2009;8:28.
 76. Cojean S, Hubert V, Le Bras J, Durand R. Resistance to dihydroartemisinin. 
Emerg Infect Dis. 2006;12:1798–9.
 77. Legrand E, Volney B, Meynard JB, Mercereau-Puijalon O, Esterre P. In vitro 
monitoring of Plasmodium falciparum drug resistance in French Guiana: 
a synopsis of continuous assessment from 1994 to 2005. Antimicrob 
Agents Chemother. 2008;52:288–98.
 78. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, et al. A major 
genome region underlying artemisinin resistance in malaria. Science. 
2012;336:79–82.
 79. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp 
AM, et al. Genetic loci associated with delayed clearance of Plasmodium 
falciparum following artemisinin treatment in Southeast Asia. Proc Natl 
Acad Sci USA. 2013;110:240–5.
 80. Amambua-Ngwa A, Tetteh KK, Manske M, Gomez-Escobar N, Stewart LB, 
Deerhake ME, et al. Population genomic scan for candidate signatures of 
balancing selection to guide antigen characterization in malaria parasites. 
PLoS Genet. 2012;8:e1002992.
 81. Lucchi NW, Komino F, Okoth SA, Goldman I, Onyona P, Wiegand RE, et al. 
In vitro and molecular surveillance for antimalarial drug resistance in 
Plasmodium falciparum parasites in Western Kenya reveals sustained 
artemisinin sensitivity and increased chloroquine sensitivity. Antimicrob 
Agents Chemother. 2015;59:7540–7.
 82. Mekonnen SK, Aseffa A, Berhe N, Teklehaymanot T, Clouse RM, Gebru T, 
et al. Return of chloroquine-sensitive Plasmodium falciparum parasites 
and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. 
Malar J. 2014;13:244.
